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Temporal lobe epilepsy (TLE) is the most common type of epilepsy in adults where
20–30% of the patients are refractory to currently available anti-epileptic drugs. The
RhoA/Rho-kinase signaling pathway activation has been involved in inflammatory
responses, neurite outgrowth and neuronal death under pathological conditions such
as epileptic insults. Acute preventive administration of ROCK inhibitor has been reported
to have beneficial outcomes in Status Epilepticus (SE) epilepsy. In the present study, we
evaluate the effect of chronic post SE treatment with the ROCK inhibitor Y-27632 in a rat
pilocarpine model of TLE. We used chronic i.p. injections of Y-27632 for 5 days in 6 week
old control rats or rats subjected to pilocarpine treatment as a model of TLE. Surprisingly,
our findings demonstrate that a systemic administration of Y-27632 in pilocarpine-
treated rats increases neuronal death in the CA3 region and ectopic recurrent mossy
fiber sprouting (rMFS) in the dentate gyrus of the hippocampal formation. Interestingly,
we found that chronic treatment with Y-27632 exacerbates the down-regulation and
pathological distribution of the K+-Cl− cotransporter KCC2, thus providing a putative
mechanism for post SE induced neuronal death. The involvement of astrogliosis in this
mechanism appears to be intricate as ROCK inhibition reduces reactive astrogliosis
in pilocarpine rats. Conversely, in control rats, chronic Y-27632 treatment increases
astrogliosis. Together, our findings suggest that Y-27632 has a detrimental effect when
chronically used post SE in a rat pilocarpine model of TLE.
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INTRODUCTION
Temporal lobe epilepsy (TLE) is the most common type of epilepsy in adults where 20–30%
of the patients are refractory to currently available anti-epileptic drugs (Leonardi and Ustun,
2002; Engel et al., 2012). After an initial insult, both in humans and animal models, TLE is
characterized by a clinically quiescent period followed by the occurrence of spontaneous and
recurrent seizures (Cavalheiro et al., 1991; Dudek and Sutula, 2007; Curia et al., 2008). The
limbic system and, in particular, the hippocampus is one of the major seizure generation loci
(McNamara, 1994; Toyoda et al., 2013). During epileptogenesis, the hippocampus displays
substantial morphological and functional reorganizations such as excitotoxicity-mediated
cell death (Turski et al., 1983; Curia et al., 2008; Bernhardt et al., 2013), reactive gliosis
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(do Nascimento et al., 2012; Rossi et al., 2013; Hadera et al.,
2015) and subsequent ectopic recurrent mossy fiber sprouting
(rMFS; Tauck and Nadler, 1985; Represa et al., 1989; Sutula et al.,
1989; Mathern et al., 1999; Gabriel et al., 2004; de Lanerolle et al.,
2012; Peret et al., 2014) as well as GABAergic network rewiring
(Sloviter, 1987; Cossart et al., 2005). The signaling pathways and
underlying cellular and molecular mechanisms involved in this
reactive plasticity are of particular importance since they create
a powerful hyperexcitable cerebral focus that drives recurrent
disabling seizures (McNamara, 1994; Morimoto et al., 2004;
Sloviter, 2008; Jefferys, 2010; Paz and Huguenard, 2015).
The RhoA/Rho-kinase (Rho-ROCK) signaling pathway is
highly activated under pathological conditions such as spinal
cord injury, ischemia and post-traumatic epilepsy (Fournier
et al., 2003; Dubreuil et al., 2006; Ding et al., 2010). Recently, the
Rho-ROCK pathways have been involved in numerous neuronal
functions such as microglial and astroglial inflammatory
responses, neurite outgrowth and neuronal survival within
the central nervous system (for review, see Kubo et al.,
2008; Fujita and Yamashita, 2014; Hensel et al., 2015). For
instance, chronic treatment using ROCK inhibitors such as
fasudil or Y-27632 improved recovery after spinal cord injury
(Fournier et al., 2003; Boomkamp et al., 2012; Joshi et al.,
2015). Also, acute treatment with fasudil or Y-27632 promotes
neuronal survival and restrains inflammatory responses in
models of ischemia and epilepsy when used prior to insult
both in vitro and in vivo (Yamashita et al., 2007; I˙nan
and Büyükafs,ar, 2008; Ding et al., 2010; Gisselsson et al.,
2010).
Under pathophysiological conditions, GABAA-mediated
responses become depolarizing (for review, see Medina et al.,
2014). This is believed to participate in epileptogenic processes.
This includes the deregulation of functional expression of
the neuronal specific K+-Cl− co-transporter (KCC2) as
reported in resected tissues from human TLE patients (Palma
et al., 2006; Huberfeld et al., 2007; Muñoz et al., 2007) and
animal models of TLE (Pathak et al., 2007; Bragin et al.,
2009; Barmashenko et al., 2011) as well as following stroke
or traumatic brain injury (Bonislawski et al., 2007; Jaenisch
et al., 2010). In addition, recent findings show that human
mutations altering KCC2 expression levels have been linked to
epilepsy of infancy or iodiopathic epilepsy (Kahle et al., 2014;
Puskarjov et al., 2014; Stödberg et al., 2015). Both GABAA-
mediated depolarization and KCC2 downregulation could
participate in post-traumatic processes leading to neuronal
death (Shulga et al., 2008, 2012; Pellegrino et al., 2011; Medina
et al., 2014; Winkelmann et al., 2015). We have also previously
shown that depolarizing GABAergic transmission triggers the
activation of the Rho-ROCK signaling pathway, in an acute
injury model (Shulga et al., 2012). Considering the involvement
of the Rho-ROCK pathway in the pathogenesis of several
insults, ROCK seems to be a promising therapeutic target
for TLE. However, the effect of ROCK inhibitor treatment
during the early time window following Status Epilepticus
(SE) has not been investigated. In the present study, we tested
the effect of chronic treatment using the ROCK inhibitor
Y-27632, a relatively specific inhibitor at low concentrations
(Davies et al., 2000), during the early epileptogenesis period
following SE in a rat pilocarpine model of TLE. We found
that chronic treatment using the Y-27632 for 5 days
post SE exacerbates the neuronal damage and increases
early ectopic rMFS within the hippocampus during early
epileptogenesis. Moreover, we show that this was accompanied
by a downregulation of KCC2, a major regulator of chloride
homeostasis. In conclusion, our findings demonstrate that
Y-27632 exacerbates typical features of epileptogenesis which
suggest that the ROCK inhibition may not be suitable as an
anti-epileptic prophylactic drug in a rodent model of TLE.
MATERIALS AND METHODS
Animals
All experiments were approved by the Institut National de la
Santé et de la Recherche Médicale (INSERM), by the local ethic
committee (project number 66-15112012) and the European
community council directive (2010/63/UE). Adult male Wistar
rats (Charles River and Janvier Laboratories) had ad libitum
access to food and water and were single housed at 22–24◦C
under a 12 h light/dark cycle.
Rat Model of Temporal Lobe Epilepsy
Six week old male rats were treated with pilocarpine
hydrochloride (360 mg/kg, i.p.; Sigma-Aldrich) 30 min after
scopolamine methyl nitrate (0.5 mg/kg, i.p.; Sigma-Aldrich).
This pilocarpine dose was chosen because it elicited the most
severe seizures with limited mortality, as previously described by
other investigators (Esclapez et al., 1999; Artinian et al., 2011).
Animals were continuously observed to identify the onset of
SE. Pilocarpine injections resulted in continuous, repetitive
behavioral seizures (defined as SE). Behavioral rating of seizures
used the Racine scale (Racine, 1972). Stage 1 was characterized
by behavioral arrest; stage 2 by head nodding, gnawing, and mild
tremors; stage 3 by unilateral forelimb clonus; stage 4 by bilateral
forelimb clonus and stage 5 by severe seizures with prolonged
loss of postural control or prolonged tonus. The onset of SE
was defined as the time when animals experienced continuous
stage 5 seizures. Rats that did not fulfill these criteria for SE were
not included in analyses (Table 1). After 3 h of SE, convulsions
were suppressed with diazepam (8 mg/kg, i.p.; Roche) and
saline solution (0.9% NaCl; Sigma-Aldrich) was administrated
subcutaneously for re-hydratation of the animals. The injection
of diazepam was repeated as needed to help terminate behavioral
seizures up to 12 h after the end of SE. In the present study,
only male rats were subjected to pilocarpine injections, since
female rats are resistant to pilocarpine (Persinger et al., 1988;
Mejías-Aponte et al., 2002; Scharfman andMacLusky, 2014). The
variation of sex hormones is a source of variability as testoterone
and estradiol modulate seizure activity in both animal models
and human patients (Edwards et al., 1999; Smith et al., 1999,
2002; Valente et al., 2002; Galanopoulou et al., 2003; Scharfman
et al., 2005; Scharfman and MacLusky, 2006; Giorgi et al., 2014;
D’Amour et al., 2015) as well as behavioral cognitive functions in
mice model of TLE (Oliveira et al., 2015). Moreover, few studies
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TABLE 1 | Details of animals for pilocarpine induction.
Pilo + Vehicle Pilo + ROCK-I P value
Number of animals 16 24 –
Age (days) 40.42 ± 0.68 39.45 ± 0.95 0.375
Weight (grams) 192.42 ± 6.91 196.6 3 ± 3.53 0.78
Global success rate∗ 67% –
All values are mean ± SEM; Mann-Whitney test was used for significance.
∗To avoid variability each Pilo + Veh and Pilo + ROCK-I pair was taken from the
same induction session. The number of animals stated here represents 67% of the
animals that successfully went into SE. The original number of rats subjected to
pilocarpine was n = 47 animals.
have reported that KCC2 expression is sexually dimorphic and
controlled by estrogen levels (Galanopoulou and Moshé, 2003;
Nakamura et al., 2004; Perrot-Sinal et al., 2007; Galanopoulou,
2008; Giorgi et al., 2014) and that ovarian cycle induces changes
in GABAA-receptor subunits and subsequent inhibition (Stell
et al., 2003; Maguire et al., 2005; Maguire andMody, 2007). Thus,
these phenomenon could alter the response to drug affecting the
GABAergic system under epileptic conditions (Scharfman and
MacLusky, 2014).
ROCK Inhibitor Y-27632 Treatment
Y-27632 (Y0503, Sigma-Aldrich) was dissolved in 0.9% NaCl
and injected intraperitoneally two times per day at a dose of
10 mg/kg in a volume of 0.1 ml per 100 g of body weight.
Pilocarpine animals injected with Y-27632 were treated from the
1st day to the 5th day post SE. Pilocarpine-treated vehicle animals
received a volume of saline solution (0.1 ml per 100 g of body
weight). The saline or ROCK inhibitor Y-27632 treatment was
administrated from 8–24 h after the last injection of diazepam
(8–24 h after termination of behavioral seizures). Age, weight and
strain matching control animals were injected intraperitoneally,
two times per day, during 5 days with saline (0.9% NaCl) or Y-
27632 at a dose of 10 mg/kg in a volume of 0.1 ml per 100 g of
body weight, and received the same total number of injection
than pilocarpine-treated rats.
Immunohistochemstry
Rats were anesthetized with isoflurane prior to the i.p. injection
of 40 mg/kg of pentobarbital and transcardiacally perfused
with cold phosphate buffer saline (PBS, 1 M) prior to cold
4% paraformaldehyde in PBS. Brains were post-fixed overnight
in 4% paraformaldehyde in PBS at 4◦C and then coronally
cut with a Leica VT1200S Vibratome (60 µm thick-sections).
Sections were then permeabilized and blocked in PBS with
0.3% Triton X-100 and 5% normal goat serum (NGS) for
1 h at room temperature. Incubation with primary antibodies
diluted in PBS with 5% NGS and 0.1% Triton X-100 was
carried out at 4◦C overnight using rabbit-KCC2 (home product,
Ludwig et al., 2003; 1/4000), mouse-SPO (Synaptoporin, Synaptic
Systems, 1/800), mouse-NeuN (Millipore, 1/1000) and rabbit-
GFAP (Sigma, 1/1000). After rinsing three times in PBS, slices
were incubated with the corresponding Alexa Fluor-conjugated
secondary antibodies diluted in PBS (1/1000, Invitrogen) for 1 h
TABLE 2 | Details of animals, sections and ROIs used for the study.
Pilo + Veh Pilo + ROCK-I Ctrl + Veh Ctrl + ROCK-I
Number of animals 16 24 12 16
Number of section 5 5 5 5
per animal
Number of ROIs 50 50 50 50
per animal
(for KCC2 plot
profile analysis)
at room temperature and finally counterstained for 5 min with
Hoechst 33258 (10 µg/ml in PBS, Sigma-Aldrich). Sections were
then mounted onto Superfrost Plus glass slides in Fluoromount
G mounting medium or Permount medium for Fluorojade-B
protocol. For each section, images were taken using a 10× or
20× objective using the same microscope (Axioplan2, Zeiss) and
camera (AxiocanMRm, Zeiss) settings. Fluorojade-B staining
protocol has been performed following Schmued and Hopkins
(2000).
Quantification
KCC2 analysis was performed in blind. In control vehicle-
and Y-27632-treated, pilocarpine vehicle- and Y-27632-treated
rats, intensity and distribution analyses of KCC2 fluorescence,
associated with the membrane or cytosolic regions, were
performed on 50 CA3 pyramidal cells randomly selected for
each animal condition (Table 2). On each cell, we applied
the same straight line from the nucleus to the external cell
compartment. The plot profile values were obtained using
Plot analysis from Fiji software and the mean ± S.E.M are
represented in the figure. The global fluorescence intensity
analysis of KCC2 has been normalized to the number
of cells contained in the ROIs. The 3D object counter
pluggin from Fiji software was used to count the number of
cells.
Statistical Analysis
Data are expressed as mean ± S.E.M. Statistical analyses were
performed using GraphpadPrism (GraphPad software 6.01).
For comparison between groups with normal distribution,
the two-sample unpaired or paired Student’s t test was used
for two groups. When data were not normally distributed,
the Mann–Whitney rank-sum test (for unpaired data) was
performed. For two-factor analysis, p values were determined
by Tukey multiple-comparison test following two-way ANOVA
analysis.
RESULTS
Chronic Treatment with Y-27632 after SE
Exacerbates Neuronal Cell Death During
Epileptogenesis
The ROCK-signaling pathway is strongly activated in different
trauma models including the kainate model of TLE and its acute
inhibition has been shown to have a neuroprotective effect (Jeon
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et al., 2013; Rodriguez-Perez et al., 2013). However, from a
clinical perspective it is relevant to investigate the influence of
ROCK inhibition in the early post-insult time window. Thus, we
examined the effect of daily i.p. administration of the selective
ROCK inhibitor Y-27632 from day 1 to day 5 post-SE. In
order to establish whether, under control condition, the chronic
treatment of Y-27632 affects the cell neuronal death in vivo,
we first analyzed the number of Fluorojade B-positive cells in
the CA3 region of the hippocampus of control vehicle- and
control Y-27632-treated rats (Figures 1A1,2). We observed no
Fluorojade B-positive cells in the CA3 region of vehicle- and
Y-27632-treated control rats. Similar results were found in the
hilar and CA1 regions of the hippocampus (data not shown).
Next, we evaluate the effect of chronic Y-27632 treatment on
cell death in a rat pilocarpine model (Figure 1B, experimental
paradigm). In the Y-27632-treated pilocarpine rats we observed
a statistically significant increase in the number of Fluorojade
B-positive cells (Figure 1C2) as compared to pilocarpine
vehicle-treated rats (Figure 1C1) at d5 post SE in the CA3
region of the hippocampus (Figure 1D; pilocarpine vehicle-
treated rats 40.43 ± 2.71 vs. pilocarpine Y-27632-treated rats:
62.33 ± 2.12; ∗∗∗p < 0.001). In contrary to the previously
described acute neuroprotective effects of ROCK-inhibition,
we found that the drug Y-27632 exacerbated neuronal cell
death during early epileptogenesis in a rat pilocarpine model.
Although the concentration used of the ROCK inhibitor is
similar to previously reported, there is the possibility that the
detrimental effect of Y-27632 are derived from concentration
dependent nonspecific effects. For this reason we also assessed
the effect of 5 mg/kg i.p. injection of ROCK inhibitor.
FIGURE 1 | Chronic treatment with Y-27632 after Status Epilepticus (SE) exacerbates neuronal cell death during epileptogenesis. (A) Fluorojade B
staining revealed no dead neurons in control vehicle- (A1) and Y-27632-treated animals (A2) (n = 3 for control vehicle-treated rats; n = 4 for control Y-27632-treated
rats). (B) Experimental paradigm. Six weeks old male rats were subjected to 3 h of pilocarpine-induced SE. From day 1 to day 5 post SE, the rats were i.p. injected
with either vehicle or Y-27632. (C) Fluorojade B positive cells (green) showing the dead neurons in pilocarpine vehicle- (C1) and Y-27632-treated animals (C2) in the
CA3 region. (D) The histogram shows the quantification of the number of Fluorojade B positive cells (n = 3 for pilocarpine vehicle-treated; n = 4 for pilocarpine
Y-27632-treated). Data are mean ± SEM; ∗∗∗p < 0.001, p values obtained using t test analysis Scale bars = 20 µm.
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We did not observed any effect on cell death in control
treated or pilocarpine treated animal groups (pilocarpine vehicle-
treated: 39 ± 2.43 vs. pilocarpine Y-27632-treated: 45 ± 2.32;
p = 0.105, unpaired t test, data are mean ± SEM; data not
shown).
Y-27632 Treatment Increases Early Ectopic
Recurrent Mossy Fiber Sprouting
The ectopic recurrent MF sprouting (rMFS) within the dentate
gyrus of the hippocampus is a major feature of TLE in both
human patients and animal models (Tauck and Nadler, 1985;
Represa et al., 1989; Sutula et al., 1989; Buckmaster et al.,
2002; Buckmaster, 2012). This rMFS induces a strong recurrent
excitatory circuit within the DG, and is partly responsible for
the generation of epileptiform activities in human patients and
animal models of TLE (Tauck and Nadler, 1985; Represa et al.,
1989; Epsztein et al., 2005; Peret et al., 2014; Shima et al.,
2015). Some studies suggest that rMFS is established during
the early phase of epileptogenesis (Mathern et al., 1999; Harvey
and Sloviter, 2005) and is a consequence of neuronal loss in
the CA3 region (Shetty et al., 2005). Immunohistochemical
visualization of synaptoporin (SPO) staining in the dorsal
hippocampus (Volz et al., 2011; Peret et al., 2014) revealed
a marked ectopic band within the molecular layer of DG in
pilocarpine vehicle- and Y-27632-treated rats at d5pSE (as shown
by the arrowheads in Figures 2B1,3 and Figures 2B2,4; the
granular cell layer is labeled in green using the neurotracer
marker, Figures 2A3,4–B3,4). As expected, rMFS was absent
in control conditions (as shown by the empty arrowheads in
Figures 2A1–4; both in control vehicle- and Y-27632-treated
rats). The fluorescence intensity of the ectopic band within the
molecular layer of DG was higher in pilocarpine Y-27632-treated
rats as compared to pilocarpine vehicle-treated rats (Figure 2C;
control vehicle-treated rats: 1.00± 0.17; control Y-27632-treated
rats: 1.01 ± 0.09; pilocarpine vehicle-treated rats 3.27 ± 0.12;
pilocarpine Y-27632-treated rats: 3.73 ± 0.13; ∗p < 0.05 and
∗∗∗p < 0.001). Thus, these results are in accordance with an
increased neuronal death in the CA3 region induced by ROCK
inhibition in pilocarpine rats.
Different Glial Response upon Y-27632
Treatment in Control and Post SE
Conditions
The Rho-ROCK pathway seems to play a key role in neuronal
survival and astroglial inflammatory responses (Kubo et al.,
2008). Reactive gliosis and neuronal death are major events
following SE and are thought to contribute to the pathogenesis
of TLE (McNamara, 1994; Curia et al., 2008; do Nascimento
et al., 2012). Despite the clear involvement of the Rho-ROCK
pathway in microglia activation and astrogliosis, the qualitative
effect of inhibiting this pathway may vary depending on the
experimental model (for review, see Kubo et al., 2008; Fujita and
Yamashita, 2014; Hensel et al., 2015). Moreover, few studies have
demonstrated the implication of Rho-ROCK signaling pathway
in neuronal survival and inflammatory response under epileptic
conditions (Inan and Büyükafs,ar, 2008; Jeon et al., 2013). Thus,
we investigated if the inhibitor Y-27632 influenced astrogliosis
and if this could explain the increased neuronal cell death
described at d5 post SE.
We first studied the effect of Y-27632 treatment on
astrogliosis on control rats. Surprisingly, we observed a
significant increase in GFAP fluorescence intensity in Y-27632-
treated control rats (Figure 3A2) as compared to vehicle-
treated control rats (Figure 3A1; Figure 3B, control vehicle-
treated rats 1.00 ± 0.07 vs. control Y-27632-treated rats: 1.78
± 0.09; ∗∗∗p < 0.001). The chronic ROCK inhibitor treatment
also altered the morphology of GFAP-positive astrocytes
(Figures 3A3,4). The astrocytes had a more elongated shape,
with long processes (Figure 3A4). In conclusion, our results
show that the chronic ROCK inhibitor Y-27632 treatment
under control conditions increased the astrocyte-mediated
inflammatory response which was interestingly not concomitant
to neuronal death.
Next, we evaluate the effect of chronic Y-27632 treatment
on astrogliosis in the rat pilocarpine model (see Figure 1B,
experimental paradigm). Unlike in control conditions, we
showed that reactive astrogliosis was substantially decreased in
pilocarpine Y-27632-treated rats at d5 post SE rats (Figure 3C2)
as compared to pilocarpine vehicle-treated rats (Figure 3C1)
(Figure 3D; pilocarpine vehicle-treated rats 1.00 ± 0.02 vs.
pilocarpine Y-27632-treated rats: 0.74 ± 0.02; ∗∗∗p < 0.001).
This was accompanied by morphological changes of GFAP-
positive astrocytes after ROCK inhibition, with a retraction
of the processes and astrocytes having an amyboïd shape
(Figures 3C3,4). Altogether, we showed that chronic ROCK
inhibitor Y-27632 treatment reduces astrocyte density during
epileptogenesis in the pilocarpine rat model. Thus, these data
disclose an intricate relationship between changes in astroglial
morphology and SE-induced cell death and indicate that the
effect of ROCK inhibition on neuronal cell death may largely not
depend on astroglial changes.
Y-27632 Treatment During Epileptogenesis
Alters KCC2 Expression
In addition to the neuronal loss and reactive gliosis, TLE is also
characterized by an impaired GABAergic inhibition. KCC2 is
one of the chloride co-transporter responsible for establishing
the neuronal Cl− gradient that governs GABAergic inhibition.
Under epileptic conditions, KCC2 is downregulated which leads
to impaired GABAergic inhibition in both human patients and
animal models of TLE (Palma et al., 2006; Huberfeld et al.,
2007; Pathak et al., 2007; Bragin et al., 2009; Barmashenko
et al., 2011). Importantly, recent results directly involve KCC2
in the post-traumatic events leading to neuronal cell lost
(Pellegrino et al., 2011; Winkelmann et al., 2015). With this as a
background, we assessed the effect of ROCK inhibitor Y-27632
on KCC2 expression under control and epileptic conditions.
In the CA3 region of control vehicle- and Y-27632-treated
rats, KCC2 immunostaining was strong (Figures 4A1,2); the
intensity of staining was not significantly different between the
two groups (Figure 4B; control vehicle-treated rats 1.00 ± 0.07
vs. control Y-27632-treated rats: 0.86± 0.02; p > 0.05). In control
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FIGURE 2 | Y-27632 treatment increases early ectopic recurrent mossy fiber sprouting (rMFS) in the dentate gyrus of pilocarpine rats.
Immunohistochemical staining with synaptoporin antibody (SPO, red) labeled the mossy fibers and neurotracer staining (NT, green) labeled cell body of the DG
granule cells. (A) Synaptoporin staining revealed no ectopic rMFS band in the molecular layer of the DG in both ventral and dorsal DG in control vehicle- (A1,3; empty
arrowheads) and Y-27632-treated rats (A2,4; empty arrowheads). (B) Synaptoporin staining revealed an ectopic rMFS band in the molecular layer of the DG in both
ventral and dorsal DG in pilocarpine vehicle- (B1,3; arrowheads) and Y-27632-treated rats (B2,4; arrowheads). (C) The histogram represents the quantification of the
fluorescence intensity of synaptoporin in control vehicle- and Y-27632-treated, and pilocarpine vehicle- and Y-27632-treated rats. The data are normalized to control
vehicle-treated rats (n = 3 for control vehicle-treated rats; n = 4 for control Y-27632-treated rats; n = 3 for pilocarpine vehicle-treated; n = 4 for pilocarpine
Y-27632-treated). Data are means ± SEM; ∗p < 0.05; ∗∗∗p < 0.001, p values were determined by Tukey multiple-comparison test following two-way ANOVA
analysis. Scale bar = 20 µm.
Y-27632-treated rats, similar intensity and pattern of expression
was observed (Figures 4A3,4). At higher magnification, we can
see that KCC2 immunolabeling is expressed in the perisomatic
region of CA3 pyramidal cells (stained using NeuN antibody) in
both conditions (Figures 4A1,2 and insert boxes). To confirm
these observations, we analyzed the intensity and repartition of
KCC2 plotted as a function of pixel distance across the soma.
The overall pattern of expression of KCC2 is comparable in
control vehicle- and Y-27632-treated rats with a narrow peak at
the perisomatic level (Figure 4C, arrowhead); with a significantly
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FIGURE 3 | Different glial responses upon Y-27632 treatment in control and post-SE conditions. (A) Representative images of GFAP-immunopositive
astrocytes (green) in control vehicle-treated (A1,3) and Y27632-treated (A2,4) rats. Dotted lines indicate the pyramidal cell layer of the CA3. The white squares in
(A1,2) show higher magnifications of GFAP labeling (A3,4). (B) The histogram represents the quantification of the fluorescence intensity (n = 3 for control
vehicle-treated; n = 4 for control Y-27632-treated). Data are means ± SEM; ∗∗∗p < 0.001, p values obtained using Mann–Whitney rank-sum test analysis.
(C) Representative images of GFAP-immunopositive astrocytes (green) in the CA3 region in pilocarpine vehicle-treated (C1,3) and pilocarpine Y27632-treated (C2,4)
rats. Dotted lines indicate the pyramidal cell layer of the CA3 region. The white squares in (C1,2) show higher magnifications of GFAP labeling (C3,4).
(D) The histogram represents the quantification of the fluorescence intensity (n = 4 for pilocarpine vehicle-treated; n = 8 for pilocarpine Y-27632-treated). Data are
means ± SEM; ∗∗∗p < 0.001, p values obtained using Mann–Whitney rank-sum test analysis. Scale bars: A1, 2; C1, 2 = 20µm. A3, 4; C3, 4 = 15 µm.
but minor difference in the cytoplasm and in the external part of
the cells (Figure 4C, asterisks, p< 0.05). Those results prompt us
to conclude that ROCK inhibitor Y-27632 has no overall effect
on KCC2 expression pattern under control conditions.
We next investigated the effect of ROCK inhibitor Y-27632
treatment on KCC2 expression in the pilocarpine rats.
Interestingly, we observed a lower KCC2 immunoreactvity
in the CA3 pyramidal layer as well as in layers containing
the dendritic trees (stratum oriens and stratum radiatum) in
pilocarpine Y-27632-treated rats (Figures 4D2,4) as compared
to pilocarpine vehicle-treated rats (Figures 4D1,3). These
observations were confirmed by the analysis of fluorescence
intensity showing a significantly decreased intensity in
pilocarpine Y-27632-treated rats as compared to pilocarpine
vehicle-treated rats (Figure 4E; pilocarpine vehicle-treated
rats 1.00 ± 0.08 vs. control Y-27632-treated rats: 0.53 ± 0.04;
∗p < 0.05). The intensity and repartition analysis of KCC2
staining show that KCC2 was very low and diffuse within
the neuron cell bodies in both conditions (Figures 4D,F). In
pilocarpine Y-27632-treated rats, the cytoplasmic levels of KCC2
immunostaining were significantly decreased as compared to
pilocarpine vehicle-treated (Figure 4F, ∗∗∗p < 0.01). Moreover,
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FIGURE 4 | Y-27632 treatment during epileptogenesis alters KCC2 expression in the CA3 region. (A) Immunohistochemical stainings with KCC2 antibody
(red) and NeuN (green) in the CA3 region of control vehicle- (A1,3) and Y-27632-treated animals (A2,4). The white squares in (A1–4) show higher magnifications of
KCC2 labeling. (B) The histogram represents the quantification of the fluorescence of KCC2 labeling in control vehicle- and Y-27632-treated animals. The data are
normalized to control. (C) The curves represent the plot profile of KCC2 staining along 10 µm from the nucleus to the external neuropil of the neurons analyzed. The
arrowhead indicates the putative membrane location (n = 3 for control vehicle-treated; n = 4 for control Y-27632-treated). (D) Immunohistochemical stainings with
KCC2 antibody (red) and NeuN (green) in the CA3 region in pilocarpine vehicle- (D1,3) or with Y-27632-treated animals (D2,4). The white squares in (D1–4) show
higher magnifications of KCC2 labeling. (E) The histogram represents the quantification of the fluorescence of KCC2 labeling in pilocarpine vehicle- or with
Y-27632-treated animals. The data are normalized to pilocarpine vehicle-treated rats. (F) The curves represent the plot profile of KCC2 staining along 10 µm from the
nucleus to external neuropil of the neurons analyzed (n = 4 for pilocarpine vehicle-treated; n = 8 for pilocarpine Y-27632-treated). Data are means ± SEM; ∗p < 0.05;
∗∗∗p < 0.001, p values obtained using t test analysis. Scale bars = 20 µm.
we also assessed the effect of 5 mg/kg i.p. injection of ROCK
inhibitor and did not observed any effect on KCC2 expression
in control treated or pilocarpine treated animal groups (control
vehicle-treated: 1.00 ± 0.09; control Y-27632-treated: 1.03
± 0.12; p = 0.65, unpaired t test; pilocarpine vehicle-treated:
1.00 ± 0.11 vs. pilocarpine Y-27632-treated: 0.90 ± 0.11;
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p = 0.54, unpaired t test, data are mean ± SEM; data not
shown).
Altogether, these results show that chronic ROCK inhibitor
Y-27632 treatment has a detrimental effect on KCC2 expression
during epileptogenesis and not under control conditions. Thus,
we found that chronic ROCK inhibition treatment exacerbates
the pilocarpine-induced down-regulation of KCC2 and this
could play an important role in the mechanism mediating the
neuronal loss induced by this inhibitor during epileptogenesis.
DISCUSSION
The RhoA pathway and its downstream effector ROCK
are activated under various pathological conditions including
Alzheimer’s (Zhou et al., 2003) and Parkinson’s diseases
(Rodriguez-Perez et al., 2013), spinal cord injury (Fournier et al.,
2003), global cerebral ischemia (Castro-Alvarez et al., 2011),
traumatic brain injury (Dubreuil et al., 2006) as well as in
epilepsy (Dubreuil et al., 2006; Inan and Büyükafs,ar, 2008; Jeon
et al., 2013). Besides, the ROCK signaling pathway is involved in
numerous fundamental cellular functions such as cell adhesion,
apoptosis, inflammatory responses and neurite outgrowth (see
for review, Kubo et al., 2008; Fujita and Yamashita, 2014;
Hensel et al., 2015). To this end, several drugs such as Fasudil
or Y-27632 have been developed to inhibit ROCK activity
in order to treat the diverse pathological conditions where
RhoA-ROCK signaling pathway is activated (Kubo et al., 2008).
Importantly, ROCK inhibition using Y-27632 has an acute
antiepileptic effect in the PTZ model of epilepsy (Inan and
Büyükafs,ar, 2008), as well as a neuroprotective effect in KA-
induced SE when applied acutely prior to the SE (Jeon et al.,
2013). Thus, although the acute effect of ROCK inhibition
is established, it was desirable to evaluate the impact of the
use of inhibitors of this pathway in the early post-SE time
window.
In the present study, we have evaluated the effect of chronic
ROCK inhibitor Y-27632 treatment during the early phase
of epileptogenesis in the rat pilocarpine model. Interestingly,
our results uncovered a differential effect of ROCK inhibitor
treatment between control and epileptic conditions. Unlike
the positive acute effect of ROCK inhibition when applied
prior to the onset of SE, we found that chronic Y-27632
treatment after SE resulted in a significant increase in cell
death in pilocarpine rats which was followed by augmented
ectopic rMFS during early epileptogenesis at d5 post SE.
These results could no be explained by an increased reactive
astrogliosis after ROCK inhibition as the specific compound
Y-27632 reduced reactive astrogliosis during epileptogenesis.
Interestingly, we found that Y-27632 treatment exacerbates
KCC2 downregulation, a protein that has been recently linked
with neuronal cell death (Pellegrino et al., 2011; Winkelmann
et al., 2015). However, in control rats, this chronic treatment
did not affect cell survival, KCC2 expression, or the rMFS, but
increased astrocyte density.
One of the hallmarks of TLE is the ectopic rMFS described
in the molecular layer of the dentate gyrus within the
hippocampus (Tauck and Nadler, 1985; Represa et al., 1989;
Gabriel et al., 2004; de Lanerolle et al., 2012; Peret et al., 2014;
Shima et al., 2015). ROCK activity is involved in the axonal
outgrowth and its inhibition, using Y-27632, induces axonal
regeneration after spinal cord injury (Fournier et al., 2003).
This prompts us to evaluate the extent of ectopic rMFS after
chronic Y-27632 treatment during epileptogenesis. Here we have
shown that Y-27632 treatment increased ectopic rMFS during
early epileptogenesis. The cellular and molecular mechanisms
underlying this effect remain unclear. The extent of rMFS
has been correlated to seizure frequency (Sutula et al., 1989),
mossy cell loss (Houser, 1990; Nadler, 2003; although recently
challenged by Jinde et al., 2012) and more importantly to CA3
cell loss (Shetty et al., 2005). Thus, in the present study, the effect
of ROCK inhibition on ectopic rMFS during epileptogenesis
could also partly reflect the increased cell loss in the CA3 in the
pilocarpine model.
Although ROCK inhibition is an attractive therapeutic target,
the cellular and molecular mechanisms requiring this pathway
are far from being fully understood. ROCK activity is known
to be involved in neuronal cell death as well as astroglial
and microglial neuroinflammatory responses (Kubo et al.,
2008). The present findings show that ROCK inhibition using
Y-27632 reduced the reactive astrogliosis at d5 post SE in the
pilocarpine rats. However, Y-27632 treatment under control
conditions increased the density and modified the morphology
of astrocytes. A closer look at previous work shows, in fact,
that both effect have been observed depending on the pathology
and model considered. For instance, in hypoxia-reoxygenation
injury (Ding et al., 2010) and in neurodegenerative diseases
such as Parkinson’s disease (Barcia et al., 2012), ROCK
inhibition resulted in a reduction of microglia while in a
SOD mouse model of amyotrophic lateral sclerosis (ALS) the
ROCK inhibitor Fasudil induced an increase in microglia density
and a reduction of reactive astrogliosis (Tönges et al., 2014).
Conversely, in a spinal cord injury model, the inhibition of
ROCK using Y-27632 resulted in an increase of astrogliosis
(Chan et al., 2007). Also the results obtained in the present
study in sham treated animals are supported by previous studies
reporting that, under control conditions, either Fasudil or
Y-27632 increased astrocyte density in vivo (Chan et al., 2007);
in vitro, they induced an increase of viability and morphological
changes of astrocytes (Lau et al., 2011; O’Shea et al., 2015).
Thus, the opposite effects of Y-27632 obtained under control
and post-SE conditions suggest that the same pathway is
recruited for different cellular processes in a context dependent
manner.
Reactive gliosis has been proposed to have positive and
negative effects after CNS injury (Sofroniew, 2005; Losi et al.,
2012; Burda and Sofroniew, 2014; Jones, 2015). The astrogliosis
could mediate pro- as well as anti-inflammatory responses
and, in turn, have the potential for neural toxicity as well as
neuroprotection. Hence, the increased cell death could be a
consequence of a reduced density of reactive gliosis that is known
to help for the clearance of extracellular space, especially during
insults (Bush et al., 1999). Thus, the relationship between plastic
changes in astroglia and ROCK inhibition inducing an increase
of cell death appears to be highly complex.
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In our search for a mechanism for the increased neuronal
death following Y-27632 treatment, we ask if post-SE changes in
GABAergic transmission could be involved. An important factor
contributing to epileptogenesis is the excessive intracellular
accumulation of chloride. This leads to compromisedGABAergic
inhibition and hyperexcitability in TLE (Palma et al., 2006;
Huberfeld et al., 2007; Muñoz et al., 2007; Bragin et al.,
2009; Barmashenko et al., 2011). KCC2 is a major neuronal
chloride co-transporter which is responsible for establishing
the neuronal Cl− gradient that governs GABAergic inhibition
(Medina et al., 2014). Some studies have shown that this
transporter is downregulated during epileptogenesis in TLE
models of epilepsy (Pathak et al., 2007; Bragin et al., 2009;
Barmashenko et al., 2011). In our recent publications we
have demonstrated that: (i) GABAA-R mediated depolarization
triggers RhoA-ROCK activation in an in vitro axotomy model
(Shulga et al., 2012) and (ii) an interaction between KCC2 and
small Rho GTPases influence actin dynamics and spinogenesis
(Llano et al., 2015). In the present study, we show that
the treatment with Y-27632 for a few days post SE had
no effect under control condition but could delay the post
SE KCC2 recovery or exacerbate KCC2 downregulation in
pilocarpine rats. Previous reports have shown that excessive
glutamate levels can lead to loss of KCC2 expression and
function and the abolition of the hyperpolarizing effect of
GABAergic transmission (Lee et al., 2011). Importantly, recent
results directly linked KCC2 to proapoptotic mechanisms.
Pellegrino et al. (2011) have shown that KCC2 loss increases
cell vulnerability to toxicity and subsequent cell death. In
this study, the authors demonstrated a correlation between
the survival rate of neurons after excitotoxic insult in vitro
(30 min of 40 µM NMDA application in cultured hippocampal
neurons) and the recovery of KCC2 expression within the
24 h following the insult (Pellegrino et al., 2011). Moreover,
Winkelmann and collaborators showed an important role
of the N-terminal domain of KCC2 in glutamate induced
neuronal apoptosis (Winkelmann et al., 2015). Thus, our
data on KCC2 expression in pilocarpine rats suggest that the
ROCK signaling pathway could be involved in the recovery
of KCC2 after an excitotoxic insult, such as an SE episode,
and that this delay subsequently induce neuronal loss. This
is interesting in view that studies have shown a recovery
of KCC2 expression that could be cell type specific (e.g.,
Huberfeld et al., 2007). Thus, it will be important to investigate
whether differential ROCK signaling could be involved in this
phenomenon.
The underlying mechanisms of KCC2 downregulation seem
to involve the phosphorylation state of KCC2 (Lee et al., 2011; for
review, see Medina et al., 2014). Interestingly, in a recent report,
the activation of RhoA-ROCK-PTEN pathway was shown to
decrease the phosphorylation levels of GABAA-Rs and to trigger
endocytosis and degradation of internalized receptors (Riffault
et al., 2014). A similar mechanism could affect the expression of
KCC2 in the presence of the inhibitor Y-27632.
In conclusion, our findings evaluate for the first time the
chronic use of the ROCK inhibitor Y-27632 as a post SE
prophylactic drug during epileptogenesis in the pilocarpine
model. Our study suggests that this treatment has an overall
detrimental effect on major morphological features and neuronal
survival after SE. While the data show an intricate involvement
of astrogliosis, they suggest that post SE activation of the
ROCK pathway acts to maintain KCC2 expression. This may,
in turn, constitute part of a pro-survival mechanism during the
epileptogenic window following SE. Further investigations are
necessary to decipher, in more detail, the mechanisms of ROCK
activation in astrogliosis, rMFS and KCC2 expression in the
events leading to the development of chronic epilepsy.
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